Terlipressin

Generic Name: Terlipressin

Brand Names: Terlivaz

Drug Type: Biotech

CAS Number: 14636-12-5

Unique Ingredient Identifier: 7Z5X49W53P

Background: Terlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that acts as a vasoconstrictor. It is a prodrug of lypressin, or lysine vasopressin. Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor. As a potent vasopressor, terlipressin has been investigated in various shock states and conditions with diminished vasomotor tone. It was also studied in hepatorenal syndrome (HRS) and variceal bleeding. The drug was first approved by the FDA in September 2022.

Indication: Terlipressin is a vasopressin receptor agonist indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. The US prescribing information states that patients with a serum creatinine > 5 mg/dL are unlikely to experience benefit from terlipressin.

Associated Conditions: Hepato-Renal Syndrome, Hepatorenal Syndrome Type 1, Oesophageal varices haemorrhage, Portal Hypertension

Clinical Trials

Terlipressin for Refractory Septic Shock

Phase 2

Recruiting

Conditions: Refractory Shock
Septic Shock
Norepinephrine Adverse Reaction

Interventions: Drug: Placebo
Drug: Terlipressin

First Posted Date: 2020-04-09

Last Posted Date: 2021-09-24

Lead Sponsor: Mahidol University

Target Recruit Count: 130

Registration Number: NCT04339868

Locations: 🇹🇭
Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

The Effect of Terlipressin on Recovery of Liver Function After Hepatectomy

Phase 3

Conditions: Liver Failure
Terlipressin Adverse Reaction
Ascites Hepatic
Acute Kidney Injury

Interventions: Drug: Terlipressin plus standard care
Other: Standard care

First Posted Date: 2020-01-09

Last Posted Date: 2020-01-09

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 86

Registration Number: NCT04221672

Locations: 🇨🇳
Ruijin Hospital Affiliated To Shanghai Jiaotong University, Shanghai, Shanghai, China
🇨🇳
Xinhua Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, Shanghai, China
🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

and more 1 locations

2- Day vs. 5- Day Terlipressin and Ceftriaxone in the Control Acute Gastroesophageal Variceal Hemorrhage

Phase 4

Conditions: Variceal Rebleeding Rate and Infections

Interventions: Drug: Terlipressin 1Mg Powder for Conventional Release Solution for Injection Vial

First Posted Date: 2019-08-14

Last Posted Date: 2019-08-14

Lead Sponsor: E-DA Hospital

Target Recruit Count: 100

Registration Number: NCT04056806

Locations: 🇨🇳
E-Da Hospital, Kaohsiung, Taiwan

Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903)

Phase 4

Conditions: Renal Function Disorder
Acute Variceal Bleeding

Interventions: Drug: Terlipressin
Drug: Octreotide

First Posted Date: 2019-07-22

Last Posted Date: 2021-08-17

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 60

Registration Number: NCT04028323

Locations: 🇨🇳
The First Hospital of Lanzhou University, Lanzhou, Gansu, China
🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China

and more 7 locations

Terlipressin Infusion in Variceal Hemorrhage

Phase 3

Conditions: Terlipressin Adverse Reaction

Interventions: Drug: Terlipressin Injectable Product

First Posted Date: 2019-07-22

Last Posted Date: 2019-07-22

Lead Sponsor: Aga Khan University

Target Recruit Count: 128

Registration Number: NCT04028505

Locations: 🇵🇰
Aga Khan University Hospital, Karachi, Sindh, Pakistan

Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage

Completed

Conditions: Variceal Hemorrhage
Kidney Injury
Cirrhosis, Liver

Interventions: Drug: Somatostatin
Drug: Terlipressin
Drug: Octreotide

First Posted Date: 2019-02-19

Last Posted Date: 2019-07-05

Lead Sponsor: General Hospital of Shenyang Military Region

Target Recruit Count: 1682

Registration Number: NCT03846180

Locations: 🇨🇳
Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳
Department of Gastroenterology, Air Force Hospital of Northern Theater Command, Shenyang, Liaoning, China
🇨🇳
Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China

and more 11 locations